Veloxis CEO Polvino: How 'Orphan' Tacrolimus Will Beat Astellas Transplant Franchise
This article was originally published in Scrip
Executive Summary
Veloxis Pharmaceuticals A/S has received orphan drug designation from the US FDA for its recently approved extended release tacrolimus product Envarsus XR, a rare achievement for a product which contains a previously approved active ingredient. CEO William Polvino explains to Scrip why the tacrolimus-based Envarsus XR secured orphan drug status, and how it plans to compete with Astellas and its established tacrolimus franchise.